An oncology-focused biopharma company needed support to develop a pipeline of kinase inhibitors in early- and late-stage development.
Our oncologist advised the Chief Medical Officer, helped the life-cycle management team plan for supplemental indications, contributed to protocol development and arranged meetings with key opinion leaders to discuss ideas for investigator-sponsored studies.